Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2-/- Ovarian Cancer Cells.

Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE.

Mol Cancer Ther. 2020 Jan;19(1):199-210. doi: 10.1158/1535-7163.MCT-19-0242. Epub 2019 Sep 18.

PMID:
31534014
2.

Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia.

Vetter MH, Smith B, Benedict J, Hade EM, Bixel K, Copeland LJ, Cohn DE, Fowler JM, O'Malley D, Salani R, Backes FJ.

Am J Obstet Gynecol. 2020 Jan;222(1):60.e1-60.e7. doi: 10.1016/j.ajog.2019.08.002. Epub 2019 Aug 8.

PMID:
31401259
3.

Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739).

Backes FJ, Cohen D, Salani R, Cohn DE, O'Malley DM, Fanning E, Suarez AA, Fowler JM.

Gynecol Oncol. 2019 Jun;153(3):496-499. doi: 10.1016/j.ygyno.2019.03.252. Epub 2019 Apr 4.

PMID:
31230614
4.

The effect of preoperative nutritional status on postoperative complications and overall survival in patients undergoing pelvic exenteration: A multi-disciplinary, multi-institutional cohort study.

Lyell NJ, Kitano M, Smith B, Gleisner AL, Backes FJ, Cheng G, McCarter MD, Abdel-Misih S, Jones EL.

Am J Surg. 2019 Aug;218(2):275-280. doi: 10.1016/j.amjsurg.2019.03.021. Epub 2019 Apr 4.

PMID:
30982571
5.

Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer.

Hutchcraft ML, Smith B, McLaughlin EM, Hade EM, Backes FJ, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ, Salani R.

Gynecol Oncol. 2019 May;153(2):255-258. doi: 10.1016/j.ygyno.2019.01.026. Epub 2019 Feb 2.

PMID:
30718123
6.

Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.

Backes FJ, Haag J, Cosgrove CM, Suarez A, Cohn DE, Goodfellow PJ.

Cancer. 2019 Feb 1;125(3):398-405. doi: 10.1002/cncr.31901. Epub 2018 Dec 18.

7.

Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.

Vetter MH, Khan A, Backes FJ, Bixel K, Cohn DE, Copeland LJ, Fowler JM, Salani R, Li Q, O'Malley DM.

Gynecol Oncol. 2019 Feb;152(2):316-321. doi: 10.1016/j.ygyno.2018.10.037. Epub 2018 Nov 29.

PMID:
30503265
8.

The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series.

Nguyen MC, Shah MH, Liebner DA, Backes FJ, Phay J, Shirley LA.

J Natl Compr Canc Netw. 2018 Nov;16(11):1279-1283. doi: 10.6004/jnccn.2018.7059.

PMID:
30442730
9.

Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.

ElNaggar AC, Hade EM, O'Malley DM, Liang MI, Copeland LJ, Fowler JM, Salani R, Backes FJ, Cohn DE.

Gynecol Oncol. 2018 Dec;151(3):501-505. doi: 10.1016/j.ygyno.2018.09.014. Epub 2018 Sep 30.

PMID:
30282591
10.

Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.

Neff R, Rush CM, Smith B, Backes FJ, Cohn DE, Goodfellow PJ.

Int J Cancer. 2018 Dec 1;143(11):2955-2961. doi: 10.1002/ijc.31784. Epub 2018 Sep 29.

11.

Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.

Felix AS, Sinnott JA, Vetter MH, Rhoades J, Cohn DE, Backes FJ, Sherman ME, Suarez AA.

Gynecol Oncol. 2018 Jul;150(1):38-43. doi: 10.1016/j.ygyno.2018.05.005. Epub 2018 May 10.

12.

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA.

Gynecol Oncol. 2018 Feb;148(2):275-280. doi: 10.1016/j.ygyno.2017.11.018. Epub 2017 Nov 28.

13.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11.

14.

Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.

Li Z, Joehlin-Price AS, Rhoades J, Ayoola-Adeola M, Miller K, Parwani AV, Backes FJ, Felix AS, Suarez AA.

Int J Gynecol Cancer. 2018 Jan;28(1):59-68. doi: 10.1097/IGC.0000000000001120.

PMID:
29053481
15.

Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ; Ovarian Cancer Association Consortium, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):396-401. doi: 10.1016/j.ygyno.2017.08.024. Epub 2017 Sep 19.

16.

Influence of tumor size on outcomes following pelvic exenteration.

Smith B, Jones EL, Kitano M, Gleisner AL, Lyell NJ, Cheng G, McCarter MD, Abdel-Misih S, Backes FJ.

Gynecol Oncol. 2017 Nov;147(2):345-350. doi: 10.1016/j.ygyno.2017.08.014. Epub 2017 Aug 16.

PMID:
28822555
17.

Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care.

Senter L, O'Malley DM, Backes FJ, Copeland LJ, Fowler JM, Salani R, Cohn DE.

Gynecol Oncol. 2017 Oct;147(1):110-114. doi: 10.1016/j.ygyno.2017.07.141. Epub 2017 Aug 8.

PMID:
28800943
18.

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.

Cosgrove CM, Cohn DE, Hampel H, Frankel WL, Jones D, McElroy JP, Suarez AA, Zhao W, Chen W, Salani R, Copeland LJ, O'Malley DM, Fowler JM, Yilmaz A, Chassen AS, Pearlman R, Goodfellow PJ, Backes FJ.

Gynecol Oncol. 2017 Sep;146(3):588-595. doi: 10.1016/j.ygyno.2017.07.003. Epub 2017 Jul 11.

19.

Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations.

Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, Rossi EC, Tanner EJ, Wolsky RJ.

Gynecol Oncol. 2017 Aug;146(2):405-415. doi: 10.1016/j.ygyno.2017.05.027. Epub 2017 May 28. Review.

20.

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, Miller DS.

Gynecol Oncol. 2017 Jun;145(3):519-525. doi: 10.1016/j.ygyno.2017.03.017. Epub 2017 Apr 6.

21.

Sparse feature selection for classification and prediction of metastasis in endometrial cancer.

Ahsen ME, Boren TP, Singh NK, Misganaw B, Mutch DG, Moore KN, Backes FJ, McCourt CK, Lea JS, Miller DS, White MA, Vidyasagar M.

BMC Genomics. 2017 Mar 27;18(Suppl 3):233. doi: 10.1186/s12864-017-3604-y.

22.

Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.

Cohn DE, Backes FJ, Wallbillich JJ, Bixel K, Crafton SM, Neff R, ElNaggar AC, Smith B, Suarez AA.

Gynecol Oncol. 2017 Mar;144(3):451-455. doi: 10.1016/j.ygyno.2017.01.023. Epub 2017 Feb 1.

PMID:
28161140
23.

Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Winder AD, Maniar KP, Wei JJ, Liu D, Scholtens DM, Lurain JR, Schink JC, Buttin BM, Filiaci VL, Lankes HA, Ramirez NC, Park K, Singh M, Lieberman RW, Mannel RS, Powell MA, Backes FJ, Mathews CA, Pearl ML, Secord AA, Peace DJ, Mutch DG, Creasman WT, Kim JJ.

Cancer. 2017 Apr 1;123(7):1144-1155. doi: 10.1002/cncr.30477. Epub 2016 Dec 7.

24.

Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?

Smith B, McCann GA, Phillips G, Backes FJ, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ, Salani R.

Gynecol Oncol. 2017 Feb;144(2):290-293. doi: 10.1016/j.ygyno.2016.11.029. Epub 2016 Nov 21.

PMID:
27884514
25.

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD.

Cancer. 2017 May 15;123(6):985-993. doi: 10.1002/cncr.30414. Epub 2016 Nov 16.

26.

Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort.

Backes FJ, ElNaggar AC, Farrell MR, Brudie LA, Ahmad S, Salani R, Cohn DE, Holloway RW, Fowler JM, O'Malley DM.

Int J Gynecol Cancer. 2016 Nov;26(9):1717-1721. Erratum in: Int J Gynecol Cancer. 2017 Jan;27(1):193.

PMID:
27575633
27.

The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.

Smith B, Neff R, Cohn DE, Backes FJ, Suarez AA, Mutch DG, Rush CM, Walker CJ, Goodfellow PJ.

Gynecol Oncol. 2016 Nov;143(2):398-405. doi: 10.1016/j.ygyno.2016.08.237. Epub 2016 Aug 15.

28.

The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas.

Joehlin-Price AS, McHugh KE, Stephens JA, Li Z, Backes FJ, Cohn DE, Cohen DW, Suarez AA.

Am J Surg Pathol. 2017 Jan;41(1):49-55.

29.

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino R, Broaddus RD, Ramirez N, Gao F, Ali S, Darcy KM, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

J Clin Oncol. 2016 Sep 1;34(25):3062-8. doi: 10.1200/JCO.2016.67.8722. Epub 2016 Jun 20.

30.

A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease.

Cowan RA, Black DR, Hoang LN, Park KJ, Soslow RA, Backes FJ, Gardner GJ, Abu-Rustum NR, Leitao MM Jr, Eisenhauer EL, Chi DS.

Gynecol Oncol. 2016 Jul;142(1):139-143. doi: 10.1016/j.ygyno.2016.04.028. Epub 2016 May 5.

31.

Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.

Backes FJ, Walker CJ, Goodfellow PJ, Hade EM, Agarwal G, Mutch D, Cohn DE, Suarez AA.

Gynecol Oncol. 2016 May;141(2):312-317. doi: 10.1016/j.ygyno.2016.03.006. Epub 2016 Mar 10.

32.

Late side effects of robotic surgery.

Backes FJ, Fowler JM.

Gynecol Oncol. 2016 Mar;140(3):375-6. doi: 10.1016/j.ygyno.2016.02.009. No abstract available.

PMID:
26905434
33.

Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI.

Billingsley CC, Cansino C, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ, Backes FJ, Salani R.

Gynecol Oncol. 2016 Mar;140(3):405-8. doi: 10.1016/j.ygyno.2016.01.020. Epub 2016 Jan 20.

PMID:
26801939
34.

A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer.

Cohn DE, Castellon-Larios K, Huffman L, Salani R, Fowler JM, Copeland LJ, O'Malley DM, Backes FJ, Eisenhauer EL, Abdel-Rasoul M, Puente EG, Bergese SD.

J Minim Invasive Gynecol. 2016 Mar-Apr;23(3):429-34. doi: 10.1016/j.jmig.2016.01.002. Epub 2016 Jan 8.

PMID:
26776677
35.

Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

Joehlin-Price AS, Stephens JA, Zhang J, Backes FJ, Cohn DE, Suarez AA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):438-45. doi: 10.1158/1055-9965.EPI-15-1145. Epub 2015 Dec 18.

36.

Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation.

Crafton S, Nekkanti S, Lynch C, Cohn DE, Fowler JM, Copeland LJ, O'Malley DM, Salani R, Backes FJ, Eisenhauer EL.

Int J Gynecol Cancer. 2016 Jan;26(1):35-42. doi: 10.1097/IGC.0000000000000576.

PMID:
26658364
37.

Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.

Liang MI, ElNaggar AC, Nekkanti S, O'Malley DM, Hade EM, Copeland LJ, Fowler JM, Salani R, Backes FJ, Cohn DE.

Gynecol Oncol. 2015 Sep;138(3):689-93. doi: 10.1016/j.ygyno.2015.07.094. Epub 2015 Jul 26.

PMID:
26216728
38.

Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy.

Billingsley CC, Jacobson SN, Crafton SM, Crim AK, Li Q, Hade EM, Cohn DE, Fowler JM, Copeland LJ, Salani R, Backes FJ, O'Malley DM.

Int J Gynecol Cancer. 2015 Sep;25(7):1331-6. doi: 10.1097/IGC.0000000000000487.

PMID:
26067861
39.

Intraoperative radiation therapy (IORT) for gynecologic malignancies.

Backes FJ, Martin DD.

Gynecol Oncol. 2015 Aug;138(2):449-56. doi: 10.1016/j.ygyno.2015.05.030. Epub 2015 May 29. Review.

PMID:
26033307
40.

Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative Complications.

Backes FJ, Rosen M, Liang M, McCann GA, Clements A, Cohn DE, OʼMalley DM, Salani R, Fowler JM.

Int J Gynecol Cancer. 2015 Sep;25(7):1271-6. doi: 10.1097/IGC.0000000000000480.

PMID:
26017249
41.

The Use of Transvaginal Ultrasound in Type II Endometrial Cancer.

Billingsley CC, Kenne KA, Cansino CD, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Fowler JM, Salani R.

Int J Gynecol Cancer. 2015 Jun;25(5):858-62. doi: 10.1097/IGC.0000000000000423.

PMID:
25768078
42.

Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancer.

Liang MI, Rosen MA, Rath KS, Hade EM, Clements AE, Backes FJ, Eisenhauer EL, Salani R, O'Malley DM, Fowler JM, Cohn DE.

J Minim Invasive Gynecol. 2015 May-Jun;22(4):583-9. doi: 10.1016/j.jmig.2014.12.167. Epub 2015 Jan 5.

PMID:
25573182
43.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9. doi: 10.1097/IGC.0000000000000264. Review.

PMID:
25341586
44.

Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.

Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54. doi: 10.1097/IGC.0000000000000223. Review.

PMID:
25341580
45.

Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?

Backes FJ, Billingsley CC, Martin DD, Tierney BJ, Eisenhauer EL, Cohn DE, O'Malley DM, Salani R, Copeland LJ, Fowler JM.

Gynecol Oncol. 2014 Oct;135(1):95-9. doi: 10.1016/j.ygyno.2014.07.093. Epub 2014 Jul 30.

PMID:
25084510
46.

Imaging across the life span: innovations in imaging and therapy for gynecologic cancer.

Xu-Welliver M, Yuh WT, Fielding JR, Macura KJ, Huang Z, Ayan AS, Backes FJ, Jia G, Moshiri M, Zhang J, Mayr NA.

Radiographics. 2014 Jul-Aug;34(4):1062-81. doi: 10.1148/rg.344130099.

47.

Training the next generation of robotic surgeons using guided mentorship: a randomized controlled trial.

Liang MI, McCann GA, Rath KS, Backes FJ, Cansino C, Salani R.

J Minim Invasive Gynecol. 2014 Nov-Dec;21(6):1075-9. doi: 10.1016/j.jmig.2014.05.011. Epub 2014 Jun 2.

PMID:
24893325
48.

Salpingectomy, why not?

Backes FJ.

Am J Obstet Gynecol. 2014 May;210(5):385-6. doi: 10.1016/j.ajog.2014.01.006. No abstract available.

PMID:
24793720
49.

Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.

Salani R, O'Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer EL.

Int J Gynecol Cancer. 2014 May;24(4):682-6. doi: 10.1097/IGC.0000000000000107.

PMID:
24651631
50.

Hysterectomy for the treatment of gynecologic malignancy.

Backes FJ, Fowler JM.

Clin Obstet Gynecol. 2014 Mar;57(1):115-27. doi: 10.1097/GRF.0000000000000006. Review.

PMID:
24488054

Supplemental Content

Loading ...
Support Center